RESEARCH PAPER
Evaluation of efficacy and regenerative potential of Wharton’s jelly and bone marrow derived mesenchymal stem cells in diabetic rats
 
More details
Hide details
1
Advanced Neurosciences Allies Indira Nagar Bangalore India
CORRESPONDING AUTHOR
Chitra Som   

Advanced Neurosciences Allies\nIndiranagar\nBangalore, India, 9th 'A' Main, off CMH Road,, Indira Nagar III Stage, Hoysala Nagar, Karnataka 560038 Bengaluru, India
 
J Pre Clin Clin Res. 2018;12(1):30–35
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Diabetes is a chronic metabolic disorder that to-date has no definitive cure. The main challenge for successful therapy to treat diabetes lies in producing functional β-cells and overcoming the autoimmune response. Currently; regenerative medicine using Mesenchymal Stem Cells (MSCs) offers promising treatment. Objective. Comparison of the antidiabetic effect of bone marrow MSCs with Wharton’s jelly MSCs in streptozotocin-induced diabetes (T1D) in rat models.

Material and methods:
Wharton’s jelly derived from human umbilical cords and bone marrows aspirated from the posterior iliac crest were used for the isolation of WJ- MSCs and BM-MSCs, respectively. MSCs were cultured and cells from passage 6 were used for the study. Experimental animals were induced with T1D using multiple low dose streptozotocin (MLDSTZ). Experimental mice were divided into 6 groups (n =10); Groups 1 and 2 were diabetic and normal controls, Groups 3 and 4 were Diabetic mice treated with WJ- MSCs and BM- MSCs, and Groups 5 and 6 were diabetic mice given insulin and glybenclamide treatments, respectively.

Results:
Low blood glucose levels, increased serum insulin levels, and significant pancreatic regeneration were observed in WJ- MSCs treated diabetic group. This was accompanied by improvement of the histopathological changes. The results were not promising in the BM-MSCs groups which had no noticeable changes.

Conclusions:
The source of MSCs from where it is procured is one of the main factors that influence the differentiation potential of MSCs into insulin producing cells. WJ-MSCs are better antidiabetic agents than BM-MSCs, and are par to the standard diabetic drugs, coupled with potential to initiate pancreatic regeneration.

 
REFERENCES (24)
1.
Yang Zhao Wenyu Ye, Kristina S Boye, John H Holcombe, Jerry A Hall, Ralph Swindle. Prevalence of other diabetes-associated complications and comorbidities and its impact on health care charges among patients with diabetic neuropathy. Journal of Diabetes and its complications 2010:24, Issue 1, 9–19.
 
2.
Liu X, Turban S, Carter R N et al. (2014) ß-Cell-Specific Glucocorticoid Reactivation Attenuates Inflammatory ß-Cell Destruction. Front Endocrinol (Lausanne) 5: 165.
 
3.
Yoon JW, Jun HS. Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus. AnnNYAcadSci. 2001 Apr; 928: 200–11.
 
4.
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813–820.
 
5.
Mabed M1, Shahin M. Mesenchymal stem cell-based therapy for the treatment of type 1 diabetes mellitus. Curr Stem Cell Res Ther. 2012; 7: 179–190.
 
6.
Fiorina P, Jurewicz M, Augello A, et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol. 2009; 183: 993–1004.
 
7.
Berman DM, Willman MA, Han D, Kleiner G, Kenyon NM, Cabrera O, Karl JA, Wiseman RW, O’Connor DH, Bartholomew AM, Kenyon NS. Mesenchymal stem cells enhance allogeneic islet engraftment in nonhuman primates. Diabetes. 2010.
 
8.
Lu D, Chen B, Liang Z, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract. 2011; 92: 26–36.
 
9.
Jansen BJ, Gilissen C, Roelofs H, Schaap-Oziemlak A, Veltman JA, Raymakers RA, Jansen JH, Kögler G, Figdor CG, Torensma R, Adema GJ. Functional differences between mesenchymal stem cell populations are reflected by their transcriptome. Stem Cells Dev. 2010; 19(4): 481–90.
 
10.
Sekiya I, Larson BL, Smith JR, Pochampally R, Cui J-G, Prockop DJ, Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality, Stem Cells 2002; 20: 530–541.
 
11.
Beane OS, Fonseca VC, Cooper LL, Koren G, Darling EM. Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells. PLoS One. 2014 Dec 26; 9(12): e115963.
 
12.
Kalaszczynska I, Ferdyn K. Wharton’s jelly derived mesenchymal stem cells: future of regenerative medicine? Recent findings and clinical significance. BioMed Res Int. 2015; 2015: 430847.
 
13.
Rydgren T, Vaarala O, Sandler S. Simvastatin protects against multiple low-dose streptozotocin-induced type 1 diabetes in CD-1 mice and recurrence of disease in nonobese diabetic mice. J Pharmacol Exp Ther. 2007 Oct; 323(1): 180–5.
 
14.
Pal R, Hanwate M, Jan M, Totey S. Phenotypic and functional comparison of optimum culture conditions for upscaling of bone marrow-derived mesenchymal stem cells. Journal of Tissue Engineering and Regenerative Medicine 2009; 3(3): 163–174.
 
15.
Singh GM, Danaei G, Farzadfar F, Stevens GA, Woodward M, Wormser DK, et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS. One. 2013; 8(7)e65174.
 
16.
Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 2008; 57: 1759–1767.
 
17.
Ben-Ami E, Berrih-Aknin S, Miller A. Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmun Rev. 2011; 10: 410–415.
 
18.
Jurewicz M, Yang S, Augello A, et al. Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes 2010; 59: 3139–3147.
 
19.
Reddi AS, Kuppasani K, Ende N. Human umbilical cord blood as an emerging stem cell therapy for diabetes mellitus. Curr Stem Cell Res Ther. 2010; 5: 356–361.
 
20.
Bárcia RN, Santos JM, Filipe M, Teixeira M, Martins JP, Almeida J, Água-Doce A, Almeida SCP, Varela A, Pohl S, Dittmar KEJ, Calado S, Simões SI, Gaspar MM, Cruz MEM, Lindenmaier W, Graça L, Cruz H, Cruz PE. What Makes Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells Superior Immunomodulators When Compared to Bone Marrow Derived Mesenchymal Stromal Cells?Stem Cells International Volume 2015, Article ID 583984.
 
21.
Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. 2011; 9: 12.
 
22.
Marcus AJ, Woodbury D. Fetal stem cells from extra-embryonic tissues: Do not discard. J Cell Mol Med. 2008; 12: 730–742.
 
23.
Chao LiGuojun WeiQun GuGang WenBaochang QiLiang XuShuqin Tao. Donor Age and Cell Passage Affect Osteogenic Ability of Rat Bone Marrow Mesenchymal Stem Cells Cell Biochemistry and Biophysics June 2015, Volume 72, Issue 2, pp 543–549.
 
24.
Weiss ML, Anderson C, Medicetty S, et al, “Immune properties of human umbilical cord Wharton’s jelly-derived cells”, Stem Cells, vol. 26, no. 11, pp. 2865–2874, 2008.
 
eISSN:1898-7516
ISSN:1898-2395